X0306 4 2022-09-27 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001650126 Choi Jung C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Common Stock 2022-09-27 4 M 0 16902 16.40 A 217940 D Common Stock 2022-09-27 4 M 0 2275 65.82 A 220215 D Common Stock 2022-09-27 4 M 0 74964 3.40 A 295179 D Common Stock 2022-09-27 4 M 0 2674 3.40 A 297853 D Common Stock 2022-09-27 4 M 0 2674 3.40 A 300527 D Common Stock 2022-09-29 5 G 0 E 73855 0.00 D 226672 D Common Stock 25000 I By Trust Stock Option (Right to Buy) 16.40 2022-09-27 4 M 0 16902 0.00 D 2027-01-16 Common Stock 16902 32098 D Stock Option (Right to Buy) 65.82 2022-09-27 4 M 0 2275 0.00 D 2030-02-02 Common Stock 2275 36225 D Stock Option (Right to Buy) 3.40 2022-09-27 4 M 0 74964 0.00 D 2025-04-08 Common Stock 74964 0 D Stock Option (Right to Buy) 3.40 2022-09-27 4 M 0 2674 0.00 D 2025-04-08 Common Stock 2674 1 D Stock Option (Right to Buy) 3.40 2022-09-27 4 M 0 2674 0.00 D 2025-04-08 Common Stock 2674 1 D The shares of Common Stock underlying the option vested in equal quarterly installments over 16 quarters from January 17, 2017 through January 17, 2021. The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. The shares of Common Stock underlying the stock option vested as to 25% of the original grant for 77,142 shares on April 6, 2016 and in 12 equal quarterly installments thereafter through April 6, 2019. On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Officer Title: Chief Business and Strategy Officer /s/ Miguel Carrillo, Attorney-in-Fact 2022-09-29